Repair of Topoisomerase I-mediated DNA Damage

Overview

Journal Prog Nucleic Acid Res Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2006 Aug 8

PMID 16891172

Citations 161

Authors

Yves Pommier

Juana M Barcelo

V Ashutosh Rao

Olivier Sordet

Andrew G Jobson

Laurent Thibaut

Ze-Hong Miao

Jennifer A Seiler

Hongliang Zhang

Christophe Marchand

Keli Agama

John L Nitiss

Christophe Redon

Affiliations

Soon will be listed here.

Citing Articles

Autophagy as a way to remove DNA lesions.

Lei Y, Klionsky D Autophagy. 2024; 21(3):497-499.

PMID: 39635883 PMC: 11849940. DOI: 10.1080/15548627.2024.2434784.

ATR safeguards replication forks against APOBEC3B-induced toxic PARP1 trapping.

Ortega P, Bournique E, Li J, Sanchez A, Santiago G, Harris B bioRxiv. 2024; .

PMID: 39605722 PMC: 11601322. DOI: 10.1101/2024.11.14.623607.

Excessive MYC-topoisome activity triggers acute DNA damage, MYC degradation, and replacement by a p53-topoisome.

Das S, Karmakar S, Venkatachalapathy H, Jha R, Batchelor E, Levens D Mol Cell. 2024; 84(21):4059-4078.e10.

PMID: 39481385 PMC: 11560571. DOI: 10.1016/j.molcel.2024.10.006.

Genome Instability Induced by Topoisomerase Misfunction.

Nitiss K, Bandak A, Berger J, Nitiss J Int J Mol Sci. 2024; 25(19).

PMID: 39408578 PMC: 11477040. DOI: 10.3390/ijms251910247.

Mechanisms controlling replication fork stalling and collapse at topoisomerase 1 cleavage complexes.

Westhorpe R, Roske J, Yeeles J Mol Cell. 2024; 84(18):3469-3481.e7.

PMID: 39236719 PMC: 7617106. DOI: 10.1016/j.molcel.2024.08.004.

References

Holm C, Covey J, Kerrigan D, Pommier Y . Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989; 49(22):6365-8. View

Pommier Y, Sordet O, Rao V, Zhang H, Kohn K . Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des. 2005; 11(22):2855-72. DOI: 10.2174/1381612054546716. View

Bahassi E, Conn C, Myer D, Hennigan R, McGowan C, Sanchez Y . Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene. 2002; 21(43):6633-40. DOI: 10.1038/sj.onc.1205850. View

Nelson W, Kastan M . DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 1994; 14(3):1815-23. PMC: 358539. DOI: 10.1128/mcb.14.3.1815-1823.1994. View

Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn K, Cushman M . Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 2003; 63(21):7428-35. View

Flatten K, Dai N, Vroman B, Loegering D, Erlichman C, Karnitz L . The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem. 2005; 280(14):14349-55. DOI: 10.1074/jbc.M411890200. View

Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou J . Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 1996; 381(6577):80-2. DOI: 10.1038/381080a0. View

Poot M, Gollahon K, Rabinovitch P . Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet. 1999; 104(1):10-4. DOI: 10.1007/s004390050903. View

Ljungman M, HANAWALT P . The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis. 1996; 17(1):31-5. DOI: 10.1093/carcin/17.1.31. View

10.

Moser B, Brondello J, Russell P . Mechanism of caffeine-induced checkpoint override in fission yeast. Mol Cell Biol. 2000; 20(12):4288-94. PMC: 85796. DOI: 10.1128/MCB.20.12.4288-4294.2000. View

11.

Wang X, Khadpe J, Hu B, Iliakis G, Wang Y . An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. J Biol Chem. 2003; 278(33):30869-74. DOI: 10.1074/jbc.M301876200. View

12.

Nitiss J, Wang J . DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A. 1988; 85(20):7501-5. PMC: 282219. DOI: 10.1073/pnas.85.20.7501. View

13.

Zhang H, Siede W . Validation of a novel assay for checkpoint responses: characterization of camptothecin derivatives in Saccharomyces cerevisiae. Mutat Res. 2003; 527(1-2):37-48. DOI: 10.1016/s0027-5107(03)00074-5. View

14.

Ahn J, Schwarz J, Piwnica-Worms H, Canman C . Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000; 60(21):5934-6. View

15.

Rao V, Fan A, Meng L, Doe C, North P, Hickson I . Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage. Mol Cell Biol. 2005; 25(20):8925-37. PMC: 1265790. DOI: 10.1128/MCB.25.20.8925-8937.2005. View

16.

Garcia-Carbonero R, Supko J . Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002; 8(3):641-61. View

17.

Zhou Y, Gwadry F, Reinhold W, Miller L, Smith L, Scherf U . Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 2002; 62(6):1688-95. View

18.

Muller M, Pfund W, Mehta V, Trask D . Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J. 1985; 4(5):1237-43. PMC: 554330. DOI: 10.1002/j.1460-2075.1985.tb03766.x. View

19.

Reid R, Fiorani P, Sugawara M, Bjornsti M . CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc Natl Acad Sci U S A. 1999; 96(20):11440-5. PMC: 18052. DOI: 10.1073/pnas.96.20.11440. View

20.

Goulaouic H, Roulon T, Flamand O, Grondard L, Lavelle F, Riou J . Purification and characterization of human DNA topoisomerase IIIalpha. Nucleic Acids Res. 1999; 27(12):2443-50. PMC: 148446. DOI: 10.1093/nar/27.12.2443. View